C-POST Trial Results: Adjuvant Immunotherapy (Cemiplimab) in Cutaneous SCC with Dr. Danny Rischin, MD

In a recent episode of MedInsights Unleashed, Dr. Danny Rischin, MD, medical oncologist/clinician researcher at the Peter MacCallum Cancer Centre and Professor, Sir Peter MacCallum Department of Oncology, University of Melbourne, discusses the groundbreaking C-POST study focused on cutaneous squamous cell cancer. By utilizing the immunotherapy drug, cemiplimab, the study achieves a 68% reduction in the risk of recurrence, marking a significant step forward in adjuvant cancer therapy. Dr. Rischin explains the study's meticulous approach to identifying high-risk patients and its impressive 87% disease-free survival rate at two years. He also discusses the role of multidisciplinary care in effectively managing complex cancer cases, emphasizing the need for continued research in uncovering reliable biomarkers.